Risk Stratification Of Men With Gleason Score 7 To 10 Tumors By Primary And Secondary Gleason Score: Results From The SEARCH Database
Main Category: Urology / NephrologyAlso Included In: Cancer / Oncology; Clinical Trials / Drug Trials
Article Date: 02 Dec 2007 - 0:00 PDT
| Patient / Public: | ![]() |
4.67 (3 votes) |
| Health Professional: | ![]() |
|
| Article Opinions: | 0 posts |
UroToday.com- In the August issue of Urology, Dr. Kang and associates from the SEARCH database report that Gleason score 7(4+3) CaP has a similar risk profile to Gleason (4+4). A Gleason cohort of 374 men was studied and included men with a Gleason score of 3+4, 4+3, or 4+4 or more. Clinical, pathologic, and biochemical outcomes were assessed in univariate and microvariate analysis.
A biopsy Gleason score of 4+3 was associated with higher risk disease than was 3+4 as noted by higher pathologic grade and more extracapsular extension (ECE) and seminal vesicle invasion (SVI). No significant differences were identified between Gleason score 4+3 and 4+4 or more in any clinicopathologic characteristic other than for higher grade pathologic tumors in the 4+4 cohort. While Gleason score 4+3 had increased odds of ECE and SVI, the 4+3 group did not differ in ECE, SVI, or positive surgical margins from the 4+4 cohort. During the follow-up period 37% experienced biochemical progression and Gleason score 4+3 were associated with an increased risk of progression relative to 3+4 but it was similar to 4+4. Furthermore, men with an RP Gleason score of 4+3 had an increased risk of progression relative to an RP Gleason score of 3+4, but it was similar to those with an RP score of 4+4. These data suggest that men with a biopsy Gleason score 4+3 should be counseled similar to those with a Gleason score 4+4, due to the risk of adverse pathologic outcomes and tumor progression.
Kang DE, Fitzsimons NJ, Presti JC, Kane CJ, Terris MK, Aronson WJ, Amling CL, Freedland SJ, SEARCH Database Study Group
Urol. 70(2): 277- 282, August 2007
doi:10.1016/j.urology.2007.03.059
Reported by UroToday.com Contributing Editor Christopher P. Evans, M.D
UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice.
To access the latest urology news releases from UroToday, go to: www.urotoday.com
----------------------------
Copyright © 2007 - UroToday
Reproduced for Medical News Today with permission of UroToday.
----------------------------
|
Please rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
| Back to top | Back to front page | List of All Medical Articles |
| Privacy Policy | Terms and Conditions | © 2009 MediLexicon International Ltd |





